MedTrace Logo

Safety and Treatment Effect of QBECO in Moderate to Severe Crohn's Disease

NCT01809275 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 68

Last updated 2016-08-23

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety profile and to obtain an indication as to the therapeutic effect of QBECO induction treatment on clinical improvement in moderate to severe Crohn's Disease.

Conditions

Interventions

DRUG

QBECO

DRUG

Placebo

Sponsors & Collaborators

  • Qu Biologics Inc.

    lead INDUSTRY

Principal Investigators

  • M D · Qu Biologics Inc.

  • M D · GI Research Institute

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-03-31
Primary Completion
2016-02-29
Completion
2016-07-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01809275 on ClinicalTrials.gov